Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren on Fibrinolytic Balance and Endothelial Function
NCT03115853Phase 4Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jun 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in hypertension (HTN), sponsored by Vanderbilt University Medical Center. Primary endpoint: Peak Plasma Plasminogen Activator Inhibitor-1 at 18 weeks. Started Jun 2009; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03115853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115853.